BR112023026510A2 - Composições e seu uso para o tratamento de deficiência de alfa1-antitripsina - Google Patents

Composições e seu uso para o tratamento de deficiência de alfa1-antitripsina

Info

Publication number
BR112023026510A2
BR112023026510A2 BR112023026510A BR112023026510A BR112023026510A2 BR 112023026510 A2 BR112023026510 A2 BR 112023026510A2 BR 112023026510 A BR112023026510 A BR 112023026510A BR 112023026510 A BR112023026510 A BR 112023026510A BR 112023026510 A2 BR112023026510 A2 BR 112023026510A2
Authority
BR
Brazil
Prior art keywords
alpha1
treatment
compositions
deficiency
antitripsin
Prior art date
Application number
BR112023026510A
Other languages
English (en)
Portuguese (pt)
Inventor
John Fox David
Andrew Huntington James
Nigel Ramsden
Original Assignee
Centessa Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centessa Pharmaceuticals Uk Ltd filed Critical Centessa Pharmaceuticals Uk Ltd
Publication of BR112023026510A2 publication Critical patent/BR112023026510A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112023026510A 2021-06-15 2022-06-15 Composições e seu uso para o tratamento de deficiência de alfa1-antitripsina BR112023026510A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2108523.8A GB202108523D0 (en) 2021-06-15 2021-06-15 Compositions and their use for the treatment of alpha1-antitrypsin deficiency
PCT/GB2022/051502 WO2022263816A1 (en) 2021-06-15 2022-06-15 COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Publications (1)

Publication Number Publication Date
BR112023026510A2 true BR112023026510A2 (pt) 2024-03-05

Family

ID=76954605

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023026510A BR112023026510A2 (pt) 2021-06-15 2022-06-15 Composições e seu uso para o tratamento de deficiência de alfa1-antitripsina

Country Status (12)

Country Link
US (1) US20240197707A1 (https=)
EP (1) EP4355328A1 (https=)
JP (1) JP7854001B2 (https=)
KR (1) KR20240027693A (https=)
CN (1) CN117794538A (https=)
AU (1) AU2022295130A1 (https=)
BR (1) BR112023026510A2 (https=)
CA (1) CA3223130A1 (https=)
GB (1) GB202108523D0 (https=)
IL (1) IL309355A (https=)
MX (1) MX2023015398A (https=)
WO (1) WO2022263816A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071621C (en) 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
WO2008143633A2 (en) 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
US8258158B2 (en) 2009-09-11 2012-09-04 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2012097371A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis
MX2020013853A (es) 2018-06-22 2021-05-27 Ucl Business Ltd Compuestos innovadores.
CA3114672A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
GB201918410D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Also Published As

Publication number Publication date
JP7854001B2 (ja) 2026-04-30
MX2023015398A (es) 2024-04-29
CN117794538A (zh) 2024-03-29
JP2024523406A (ja) 2024-06-28
EP4355328A1 (en) 2024-04-24
WO2022263816A1 (en) 2022-12-22
IL309355A (en) 2024-02-01
GB202108523D0 (en) 2021-07-28
US20240197707A1 (en) 2024-06-20
KR20240027693A (ko) 2024-03-04
CA3223130A1 (en) 2022-12-22
AU2022295130A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
BR112017017009A2 (pt) usos de um sequestrante de formaldeído e de uma composição farmacêutica, métodos para impedir, adiar, retardar ou diminuir a transformação de um composto e para tratar câncer, e, composição farmacêutica.
BR112013012740A2 (pt) sais e formas cristalinas de um agente que induz apoptose
BR112021023814A2 (pt) Inibidores de proteases de cisteína e métodos de uso das mesmas
MX2021005012A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr.
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
CL2018003418A1 (es) Formulaciones de óxido de polialquileno-asparaginasa y métodos de preparación y uso del mismo.
MX2023009388A (es) Metodos para tratar alteraciones del comportamiento.
AR048439A1 (es) Composiciones farmaceuticas y metodos para tratar la infeccion por vih
PY2295067A (es) Inhibidores del sars-cov-2 para tratar infecciones por coronavirus
MX2023002482A (es) Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
BR112023026510A2 (pt) Composições e seu uso para o tratamento de deficiência de alfa1-antitripsina
CO2023005726A2 (es) Formulación sólida
JOP20240197A1 (ar) أشكال متعددة من الأتيكابرانت للاستخدام في علاج اضطراب الاكتئاب الشديد
UY37497A (es) Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
MX2022007176A (es) 4-((2-oxopyri din-1 (2h)-yl)metil)benzamidas para el tratamiento de la deficiencia de alfa1-antitripsina.
MX2022007174A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
BR112022011566A2 (pt) Compostos e uso dos mesmos para o tratamento de deficiência de a1-antitripsina
CO2025016290A2 (es) Compuestos anti-vih
CL2008001279A1 (es) Metodo para mejorar la actividad antimicrobiana de una formulacion que comprende un aminoacido n-halogenado que comprende un agente de transferencia de fase; formulacion; metodo para desinfectar superficies y lentes de contacto; metodo para tratar una infeccion de tejido y para tratar infecciones respiratorias.
MX2024003015A (es) Nuevos derivados de quinolina.
BR112022011548A2 (pt) Compostos e uso dos mesmos para o tratamento da deficiência de a1-antitripsina
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112022011564A2 (pt) Compostos e uso dos mesmos para o tratamento da deficiência de a1-antitripsina